Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Karolinska Institutet scientists discover new approach to treat type II diabetes

Karolinska Institutet scientists discover new approach to treat type II diabetes

CSL develops new drug candidate against type 2 diabetes

CSL develops new drug candidate against type 2 diabetes

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios commences KB003 Phase 2 trial in severe asthma

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Pfizer, Visterra collaborate to discover novel antibodies

Pfizer, Visterra collaborate to discover novel antibodies

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

GE Healthcare introduces KUBio factory

GE Healthcare introduces KUBio factory

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

TaiMed, WuXi enter ibalizumab manufacturing agreement

TaiMed, WuXi enter ibalizumab manufacturing agreement

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.